As per DelveInsight’s assessment, the global aerosol delivery devices market was valued at USD 33.95 billion in 2021 and growing at a CAGR of 5.38% during the forecast period (2022 to 2027); it is anticipated to reach USD 46.50 billion by 2027. Some of the key factors such as rapidly rising cases of respiratory disorders (like asthma, chronic obstructive pulmonary disorders (COPD), and others), decreasing air quality in industrialized areas due to increasing air pollution, growing adoption of digital technology by key pharmaceutical players to provide better respiratory disorder management solutions along with the increase in product approvals are expected to stimulate the aerosol delivery devices market growth in the coming years. The leading companies in the aerosol delivery devices market include Novartis AG, AstraZeneca, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., OMRON, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH., Glenmark Pharmaceuticals Limited, Lepu Medical Technology(Beijing)Co.,Ltd., Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory., Cipla Inc., Microlife Corporation., Honsun, and others.
DelveInsight’s “Aerosol Delivery Devices Market Forecast 2027” research report provides the current and forecasted aerosol delivery devices market size, share, and trends analysis for the next five years, upcoming innovations in the segment, and major market drivers & barriers. The report also covers an in-depth assessment of the key competitors and emerging products in the domain.
Aerosol Delivery Devices Market: Overview
Aerosol delivery devices are portable devices that deliver medications for chronic obstructive pulmonary disease (COPD) and asthma into the airways. They are used to preventing and treat exacerbations of these chronic conditions. They offer the advantage of avoiding the systemic effects of drugs while ensuring that drugs are delivered right where they are needed.
To provide a better understanding of the market trends, the report covers the Aerosol Delivery Devices Market dynamics segmented by product type (dry powder inhaler, metred dose inhaler, soft mist inhalers, nebulizers [ultrasonic nebulizers, mesh nebulizers, and compressor nebulizers]), by type (conventional inhaler devices and smart inhaler devices), by patient type (adult and pediatrics), by indication (asthma, COPD, and others), and by geography.
As per the analysis, in the aerosol delivery devices type segment, the smart inhaler devices segment is expected to hold a significant market share during the forecasted period. Some of the key factors, such as the growing number of pharmaceutical companies collaborating with digital health companies to develop smart inhaler devices, rising approval of connected devices, high accuracy in drug dosage, and assisting discussions between clinicians and patients, among others, are projected to increase the demand for smart inhaler-type devices.
As per the assessment, the rising prevalence of pulmonary disorders (such as cystic fibrosis, COPD, and others) globally is one of the key factors contributing to the aerosol delivery devices market growth. Asthma is a major chronic respiratory disease affecting adults and children. In 2019, approximately 262 million people worldwide were affected by asthma, and the number of cases is expected to grow in the coming years. Therefore, the growing cases of asthma and other respiratory diseases will lead to increase demand for various aerosol delivery devices as these inhalers allow the medication to directly enter the lungs when breathed through the mouth, thereby relaxing the muscles and opening the airway, allowing more air to move in and out of the lungs for easy and comfortable breathing. The deteriorating air quality and increased air pollutants to several folds due to rapid urbanization have led to a steady increase in respiratory illness, which in turn will lead to market growth for aerosol delivery devices. Moreover, the rising product approvals and launch of vaccines and their administration across the globe and active participation of the global MedTech giants towards products are also expected to drive the market.
Despite several favorable factors, some of the key aspects, such as the lack of a single, effective device for every respiratory disorder and the availability of alternative therapies (such as oral medications and subcutaneous injections), are expected to pose a challenge to the aerosol delivery devices market growth.
Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight into Aerosol Delivery Devices Types and Emerging Products
Among all the regions, North America is expected to occupy a major share in the overall aerosol delivery devices market in the coming years. Increasing risk and rising prevalence of COPD and other respiratory disorders are expected to drive the aerosol delivery devices demand in the region. Moreover, the increase in adoption of technologically advanced aerosol delivery devices, growing product launches associated with inhalers in the region, presence of well-established healthcare facilities, and rising government initiatives to raise awareness regarding respiratory disorders and their proper management are also anticipated to drive the aerosol delivery devices Market growth in the coming years. Also, recent product approvals in the region will further augment the market for smart inhalers in the region. Furthermore, Europe and Asia-Pacific regions also have higher potential growth prospects for the global aerosol delivery devices market. The presence of key players (such as GlaxoSmithKline, AstraZeneca, and Teva pharmaceuticals, among others) and product launches are also expected to bolster the market for respiratory devices.
Interested in knowing how the market will grow by 2027? Click to get a snapshot of Aerosol Delivery Devices Market Trends and Developments
Over the years, the aerosol delivery devices market has evolved significantly owing to the active participation of global MedTech companies and technological advancements in the domain.
In recent years, some of the major advancements in the Aerosol Delivery Devices Market are –
- In September 2020, GlaxoSmithKline plc and Innoviva, Inc. received FDA approval for Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US.
- In May 2020, Propeller Health, one of the leading digital health companies dedicated to managing asthma and COPD, received FDA clearance to bring its connected platform to AstraZeneca’s Symbicort to help digitize the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- In May 2020, Iconovo received CE mark approval for its capsule-based dry powder inhaler ICOcap™ for use in clinical trials.
As per DelveInsight, the ongoing clinical & commercial development activities and research in the domain will contribute immensely to the aerosol delivery devices market growth in the coming years.
Learn more about the ongoing development in the market @ Aerosol Delivery Devices Market – Clinical and Commercial Development Activities
The leading MedTech giants in the aerosol delivery devices Market include Novartis AG, AstraZeneca, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., OMRON, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH., Glenmark Pharmaceuticals Limited, Lepu Medical Technology(Beijing)Co.,Ltd., Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory., Cipla Inc., Microlife Corporation., Honsun, and others.
As per DelveInsight, due to the very high growth rate and positive return, several new players are expected to enter the aerosol delivery devices market in the coming years. The entry of new players and the launch of emerging products will immensely drive market growth.
Learn how new players’ entries will transform the market dynamics in the coming years @ Aerosol Delivery Devices Market Trends and Competitive Landscape
Scope of the Aerosol Delivery Devices Market Report:
- Study Period – 2019-2027
- Aerosol Delivery Devices Market Assessment –
- By Product Type – Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhalers, Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, and Compressor Nebulizers]
- By Type – Conventional Inhaler Devices and Smart Inhaler Devices
- By Patient Type – Adult And Pediatrics
- By Indication – Asthma, COPD, and others
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
- Geography Covered – Global (North America, Europe, Asia-Pacific, and Rest of the World)
Table of Content
|3||Regulatory and Patent Analysis|
|4||Aerosol Delivery Devices Market Key factors analysis|
|5||Porter’s Five Forces Analysis|
|6||COVID-19 Impact Analysis on Aerosol Delivery Devices Market|
|7||Aerosol Delivery Devices Market Layout|
|8||Global Company Share Analysis – Key 3–5 Companies|
|9||Product Profiles and Key Companies|
Reach out to us to get a more detailed overview of the Aerosol Delivery Devices Market Assessment and Forecast 2027
Related Report by DelveInsight
“Chronic Obstructive Pulmonary Disease (COPD) Market” report delivers an in-depth understanding of the historical and forecasted epidemiological trends in the 7MM as well as the market size, share, and growth opportunities in the therapeutics segment. Some of the key companies in the COPD market include AstraZeneca, GlaxoSmithKline, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, United Therapeutics, Verona Pharma PLC, and others.
“Chronic Obstructive Pulmonary Disease (COPD) – Epidemiology Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology trends of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM.
“Chronic Obstructive Pulmonary Disease Pipeline Insight, 2022” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
“Severe Asthma Market” report delivers an in-depth understanding of the historical and forecasted epidemiological trends in the 7MM as well as the market size, share, and growth opportunities in the therapeutics segment. Some of the key companies in the Severe Asthma Market include Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline (GSK), Novartis, Sanofi, Regeneron Pharmaceutical, Avillion, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion, and others.
“Asthma Market” report delivers an in-depth understanding of the historical and forecasted epidemiological trends in the 7MM as well as the market size, share, and growth opportunities in the therapeutics segment.
“Asthma – Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
“Cystic Fibrosis Market” report delivers an in-depth understanding of the historical and forecasted epidemiological trends in the 7MM as well as the market size, share, and growth opportunities in the therapeutics segment. Some of the key companies in the Cystic Fibrosis Market include Verona Pharmaceuticals, Eloxx Pharmaceuticals, Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals, Vertex Pharmaceuticals, and others.
Cardiac Insufficiency Market, Onycholysis Market, Arthroscopy Devices Market, Acral Lentiginous Melanoma Market, Central Serous Chorioretinopathy Market, Cervical Cancer Market Size, Chronic Hepatitis B Virus Market, Chronic Lymphocytic Leukemia Market, Exocrine Pancreatic Insufficiency Market, Hepatic Encephalopathy Market, Hyperkalemia Market, Juvenile Rheumatoid Arthritis Market, Opioid Induced Constipation Market, Osteosarcoma MarketTreatment Resistant Depression Market, Triple Negative Breast Cancer Market, Acute Lung Injury Market, Aortic Stenosis Market
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Learn How the MedTech Devices Market is evolving with the ongoing clinical and commercial developments in the domain: MedTech Market Outlook
Manager (Marketing & Branding)